Acute lymphoblastic leukemia
 
Acute lymphoblastic leukemia (ALL) is the most common leukemia in children (representing 23% of cancer diagnoses among children younger than 15 years of age) but accounts for only 20% of adult acute leukemias. The prognosis for both childhood and adult ALL has improved remarkably with current intensive induction–consolidation–continuation (maintenance) regimens. In children, treatment now results in complete response (CR) rates of 95% and in 75–85% disease-free survival (DFS) of at least 5 years from diagnosis with current treatments that incorporate systemic therapy and specific central nervous system (CNS) therapy (Gaynon et al., 2000). The use of similar treatment . . . [Full Text of this Article]

Classification of acute lymphoblastic leukemia
Treatment of mature B-cell (Burkitt) ALL in children and adults
Treatment of precursor B- and T-cell ALL in children
Age at diagnosis
White blood cell count at diagnosis
Central nervous system status at diagnosis
Gender and race
Induction therapy
Minimal residual disease
Gene expression studies
Consolidation therapy
Central nervous system treatment
Maintenance therapy
Special groups
Relapse
Stem cell transplantation
Treatment of precursor B- and T-cell ALL in adults
Induction phase
Minimal residual disease
Consolidation therapy
CNS prophylaxis
Maintenance therapy
Philadelphia chromosome-positive ALL
Hematopoietic stem cell transplantation in adult ALL
First-remission ALL
Relapsed disease

Lymphoblastic lymphoma
 

Late complications of therapy